D&A PHARMA signs licensing and distribution agreement with Grupo JUSTE for ALCOVER® in SPAIN and Central America

D&A PHARMA signs licensing and distribution agreement with Grupo JUSTE for ALCOVER® in SPAIN and Central America

D&A PHARMA signs licensing and distribution agreement with Grupo JUSTE for ALCOVER® in SPAIN and Central America

Paris (France), Madrid (Spain), October 3, 2014 - D&A PHARMA, a leading company in the Addiction Therapy field, is pleased to announce that it has signed an exclusive Supply, Licensing and Distribution Agreement with Grupo JUSTE for ALCOVER® (Sodium Oxybate), its breakthrough treatment for alcohol dependence.

Under the terms of the agreement, Grupo JUSTE will have the exclusive marketing and distribution rights for ALCOVER® in Spain and several countries in Central America (Nicaragua, Panama, Costa Rica, Salvador, Honduras, Guatemala, Belize, and the Dominican Republic).

In addition to the initial upfront payment, D&A PHARMA will receive milestone payments plus royalties on future sales of ALCOVER® in the designated territory. D&A PHARMA will also supply Alcover ® to Grupo JUSTE.

To date, all the clinical studies conducted in Europe have demonstrated the efficacy and safety of Sodium Oxybate according to the European Medicines Agency's current evaluation criteria.

ALCOVER®, already marketed in Italy and Austria, has proved effective for the maintenance of alcohol abstinence in severe alcoholic patients, with more than 75% of patients remaining completely abstinent 6 and 12 months after initiation of treatment, with an excellent safety profile.
A decentralized procedure will be submitted in the EU in Q4 2014, including the main European countries.
Patrice Debregeas, President of D&A PHARMA, commented: "We are very pleased to announce this agreement with Grupo JUSTE, a pharma company uniquely positioned in Hispanic countries. Grupo JUSTE can draw on its considerable experience to build a powerful franchise in the addiction area and will leverage ALCOVER®'s penetration thanks to its strong local presence and regulatory expertise in Spain and Central America. This partnership is a first step in our licensing strategy. We are looking forward to pursuing it in other countries so that our treatment can swiftly become available to alcoholic patients throughout the world". 

Inés Juste, President of Grupo JUSTE added: "We are extremely satisfied to announce the arrival of this unique drug as a result of the incredible job that the D&A PHARMA team has carried out over the past seven years. Our partner D&A PHARMA possesses a deep knowledge and strong leadership in innovative treatments for addictions and this agreement will allow Grupo JUSTE to bring this new comprehensive treatment to Spain and some Latin American countries. "


***
About D&A PHARMA:
D&A PHARMA is a pharmaceutical company engaging in the development and supply of innovative treatments for various addictions such as alcohol, heroin and cocaine. The Company intends to swiftly develop its activities worldwide with ALCOVER®, a treatment for alcoholic dependence already being prescribed and marketed in Italy and Austria for which it has acquired the exclusive license. Two other molecules for heroin and cocaine addictions also under development are currently at the clinical and pre-clinical stages. Founded in 2006 by Sabine Cheyrou and Patrice Debrégeas, cofounder of Etypharm, D&A PHARMA has its headquarters in central Paris (8e Arrondissement), while its R&D and production operations are based in Houdan, 60 km west of Paris. For more information, please visit: www.da-pharma.fr

About Grupo JUSTE :
Grupo JUSTE is a Spanish corporate group with more than 90 years' experience in research, development and distribution of drugs and active pharmaceutical ingredients. Its activity is aimed at improving the quality of life of patients, with the Central Nervous System as one of its main areas of expertise since 1990 and a core strategic focus for the group.
Grupo JUSTE has two areas of activity: the Pharmaceutical Division, with broad experience in Radiology, Gynaecology, Primary Care and the Central Nervous System; and Justesa Imagen, a fine-chemicals company committed to the research, development and production of active pharmaceutical ingredients, with substantial expertise in contrast media.  The group has a significant presence in all the major world markets, directly or through partnerships with leading pharmaceutical companies. For more information, please visit: www.grupojuste.com

Contacts:
D&A PHARMA
 - +33 (0) 1 53 04 41 30
- [email protected]


Milestones Press Relations
- Bruno Arabian - +33 (0) 1 75 44 87 40 - [email protected]
Grupo JUSTE:  [email protected]
 

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.